Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

RCT (n=947) found that upacaitinib 15 mg and 30 mg once daily improved ACR50 vs weekly methotrexate (52% and 56% respectively vs 28% for methotrexate, p<0.001 for combined comparison). Rates off treatment emergent adverse effects were broadly similar.


Arthritis & Rheumatology